Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 8, Issue 7, Pages 1011
Publisher
MDPI AG
Online
2019-07-10
DOI
10.3390/jcm8071011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
- (2019) M. G. Dal Bello et al. Journal of Translational Medicine
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Circulating tumor cells count as a predictor of survival in lung cancer
- (2018) Konstantinos Syrigos et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity
- (2018) Sabrina Rossi et al. Immunotherapy
- Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study
- (2018) Scott Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging biomarkers for immune checkpoint inhibition in lung cancer
- (2018) George Cyriac et al. SEMINARS IN CANCER BIOLOGY
- The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring
- (2018) Jillian Wilhelmina Paulina Bracht et al. Current Oncology Reports
- Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer
- (2018) Etienne Giroux Leprieur et al. OncoImmunology
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
- (2018) Julie R. Brahmer et al. Journal for ImmunoTherapy of Cancer
- 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer
- (2018) Hossein Borghaei et al. Journal of Thoracic Oncology
- The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
- (2018) Joanna Kapeleris et al. Frontiers in Oncology
- Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
- (2018) Arsela Prelaj et al. EUROPEAN JOURNAL OF CANCER
- Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
- (2017) Yuki Iijima et al. EUROPEAN JOURNAL OF CANCER
- Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy
- (2017) Simona Coco et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer:18F-FDG PET/CT Study
- (2017) Silvia Morbelli et al. JOURNAL OF NUCLEAR MEDICINE
- Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis
- (2017) Sarah Cargnin et al. Journal of Thoracic Oncology
- Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
- (2017) Bing Tong et al. Oncotarget
- A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial
- (2016) M. Yanagita et al. CLINICAL CANCER RESEARCH
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials
- (2016) Jiaxing Huang et al. OncoTargets and Therapy
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
- (2016) C. Alix-Panabieres et al. Cancer Discovery
- Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer
- (2016) Bo Ai et al. Oncotarget
- Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
- (2016) Chiara Nicolazzo et al. Scientific Reports
- Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
- (2015) Claire Tissot et al. EUROPEAN RESPIRATORY JOURNAL
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer
- (2015) Zixuan Zhang et al. RESPIROLOGY
- Prognostic and predictive relevance of circulating tumor cells in patients with non-small-cell lung cancer
- (2014) Angela Alama et al. DRUG DISCOVERY TODAY
- Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment
- (2014) Laura Muinelo-Romay et al. Cancers
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib
- (2012) E. A. Punnoose et al. CLINICAL CANCER RESEARCH
- Relationship of Circulating Tumor Cells to the Effectiveness of Cytotoxic Chemotherapy in Patients With Metastatic Non-Small-Cell Lung Cancer
- (2012) Takashi Hirose et al. ONCOLOGY RESEARCH
- Plasma DNA Quantification in Lung Cancer Computed Tomography Screening
- (2008) Gabriella Sozzi et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started